EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nektar Therapeutics's Enterprise Value is $74.90 Mil.
Nektar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-250.92 Mil. Therefore, Nektar Therapeutics's EV-to-EBIT for today is -0.30.
The historical rank and industry rank for Nektar Therapeutics's EV-to-EBIT or its related term are showing as below:
NKTR'
s EV-to-EBIT Range Over the Past 10 Years
Min: -310.31 Med: -6.62 Max: 39.55
Current: -0.3
During the past 13 years, the highest EV-to-EBIT of Nektar Therapeutics was 39.55. The lowest was -310.31. And the median was -6.62.
NKTR's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs NKTR: -0.30
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nektar Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-77.71 Mil.
Nektar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-250.92 Mil. Nektar Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 322.90%.
Nektar Therapeutics EV-to-EBIT Historical Data
The historical data trend for Nektar Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nektar Therapeutics's EV-to-EBIT
For the Biotechnology subindustry, Nektar Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's EV-to-EBIT falls into.
Nektar Therapeutics EV-to-EBIT Calculation
Nektar Therapeutics's EV-to-EBIT for today is calculated as:
Nektar Therapeutics's current Enterprise Value is $74.90 Mil.
Nektar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-250.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nektar Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $-77.71 Mil.
Nektar Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-250.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Nektar Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Nektar Therapeutics (Nektar Therapeutics) Business Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NKTR has been successfully added to your 